Skip to main content

NUEVAS ESTRATEGIAS TERAPEUTICAS DIRIGIDAS AL DESARROLLO DE TRATAMIENTOS EFICACES PARA ENFERMEDADES DE ALTA INCIDENCIA

SAF2016-78792-R

•
Funding agency name Agencia Estatal de Investigación
Funding agency acronym AEI
Program Programa Estatal de I+D+i Orientado a los Retos de la Sociedad
Call Proyectos I+D+i Retos de Investigación
Call year 2016
State Plan 2013-2016 Plan Estatal de Investigación Científica y Técnica y de Innovación
Beneficiary centre UNIVERSIDAD COMPLUTENSE DE MADRID

Resultados relacionados

Resultados totales (Incluyendo duplicados): 4
Encontrada(s) 1 página(s)

Minerva. Repositorio Institucional de la Universidad de Santiago de Compostela
Publication Artículo científico (JournalArticle)

Discovery of V-0219: a small-molecule positive allosteric modulator of the Glucagon-Like Peptide-1 Receptor toward oral treatment for “diabesity”

  • Decara del Olmo, Juan Manuel
  • Vázquez Villa, Henar
  • Brea Floriani, José Manuel
  • Alonso, Mónica
  • Srivastava, Raj Kamal
  • Orio Ortiz, Laura
  • Alén Fariñas, Francisco
  • Suárez Pérez, Juan
  • Baixeras Llano, Elena
  • García Cárceles, Javier
  • Escobar Peña, Andrea
  • Lutz, Beat
  • Rodríguez, Ramón
  • Codesido, Eva
  • Garcia Ladona, F. Javier
  • Bennett, Teresa A.
  • Ballesteros, Juan A.
  • Cruces, Jacobo
  • Loza García, María Isabel
  • Benhamú Salama, Bellinda
  • Rodríguez de Fonseca, Fernando
  • López Rodríguez, María L.
Peptidic agonists of the glucagon-like peptide-1 receptor (GLP-1R) have gained a prominent role in the therapy of type-2 diabetes and are being considered for reducing food intake in obesity. Potential advantages of small molecules acting as positive allosteric modulators (PAMs) of GLP-1R, including oral administration and reduced unwanted effects, could improve the utility of this class of drugs. Here, we describe the discovery of compound 9 (4-{[1-({3-[4-(trifluoromethyl)phenyl]-1,2,4-oxadiazol-5-yl}methyl)piperidin-3-yl]methyl}morpholine, V-0219) that exhibits enhanced efficacy of GLP-1R stimulation, subnanomolar potency in the potentiation of insulin secretion, and no significant off-target activities. The identified GLP-1R PAM shows a remarkable in vivo activity, reducing food intake and improving glucose handling in normal and diabetic rodents. Enantioselective synthesis revealed oral efficacy for (S)-9 in animal models. Compound 9 behavior bolsters the interest of a small-molecule PAM of GLP-1R as a promising therapeutic approach for the increasingly prevalent obesity-associated diabetes
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

A potent isoprenylcysteine carboxylmethyltransferase (ICMT) inhibitor improves survival in ras-driven acute myeloid leukemia

  • Marín-Ramos, Nagore I.
  • Balabasquer, Moisés
  • Ortega-Nogales, Francisco J.
  • Torrecillas, I. R.
  • Gil-Ordóñez, Ana
  • Marcos-Ramiro, Beatriz
  • Aguilar-Garrido, Pedro
  • Cushman, Ian
  • Romero, Antonio
  • Medrano, Francisco Javier
  • Gajate, Consuelo
  • Mollinedo, Faustino
  • Philips, Mark R.
  • Campillo, M.
  • Gallardo, Miguel
  • Martín-Fontecha, Mar
  • López-Rodríguez, María L.
  • Ortega-Gutiérrez, S.
12 p.-9 fig.-6 tab.-1 graph. abst., Blockade of Ras activity by inhibiting its post-translational methylation catalyzed by isoprenylcysteine carboxylmethyltransferase (ICMT) has been suggested as a promising antitumor strategy. However, the paucity of inhibitors has precluded the clinical validation of this approach. In this work we report a potent ICMT inhibitor, compound 3 [UCM-1336, IC50 = 2 μM], which is selective against the other enzymes involved in the post-translational modifications of Ras. Compound 3 significantly impairs the membrane association of the four Ras isoforms, leading to a decrease of Ras activity and to inhibition of Ras downstream signaling pathways. In addition, it induces cell death in a variety of Ras-mutated tumor cell lines and increases survival in an in vivo model of acute myeloid leukemia. Because ICMT inhibition impairs the activity of the four Ras isoforms regardless of its activating mutation, compound 3 surmounts many of the common limitations of available Ras inhibitors described so far. In addition, these results validate ICMT as a valuable target for the treatment of Ras-driven tumors., This work was supported by grants from the Spanish MINECO (Grants SAF2016-78792-R, SAF2017-89672-R) and predoctoral fellowships from CEI Moncloa (N.I.M.-R.), MINECO (M.B. and F.J.O.), and Fundación La Caixa (A.G.-O.)., Peer reviewed
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Development of a Nucleotide Exchange Inhibitor That Impairs Ras Oncogenic Signaling

  • Marín-Ramos, Nagore I.
  • Piñar, Carmen
  • Vazquez-Villa, Henar
  • Martín-Fontecha, Mar
  • González, Ángel
  • Canales, Ángeles
  • Algar, S.
  • Mayo, Paloma P.
  • Jiménez-Barbero, Jesús
  • Gajate, Consuelo
  • Mollinedo, Faustino
  • Pardo, Leonardo
  • Ortega-Gutiérrez, S.
  • Viso, Alma
  • López-Rodríguez, María L.
Despite more than three decades of intense effort, no anti-Ras therapies have reached clinical application. Contributing to this failure has been an underestimation of Ras complexity and a dearth of structural information. In this regard, recent studies have revealed the highly dynamic character of the Ras surface and the existence of transient pockets suitable for small-molecule binding, opening up new possibilities for the development of Ras modulators. Herein, a novel Ras inhibitor (compound 12) is described that selectively impairs mutated Ras activity in a reversible manner without significantly affecting wild-type Ras, reduces the Ras–guanosine triphosphate (GTP) levels, inhibits the activation of the mitogen-activated protein kinase (MAPK) pathway, and exhibits remarkable cytotoxic activity in Ras-driven cellular models. The use of molecular dynamics simulations and NMR spectroscopy experiments has enabled the molecular bases responsible for the interactions between compound 12 and Ras protein to be explored. The new Ras inhibitor binds partially to the GTP-binding region and extends into the adjacent hydrophobic pocket delimited by switch II. Hence, Ras inhibitor 12 could represent a new compound for the development of more efficacious drugs to target Ras-driven cancers; a currently unmet clinical need., This work was supported by ExonHit Therapeutics and bygrants from the Spanish Ministerio de EconomíaayCompetitividad (MINECO, SAF2013-48271-R, SAF2014-59716-R, and SAF2016-78792-R) and Comunidad de Madrid (S2010/BMD-2353). We thank the Campus de Excelencia CEI Moncloa fora predoctora lfellowship to N.I.M.-R.,the UCM’sCAI Cytometryand Fluorescence Microscopy for their assistance, and the com-puter resources provided by the Barcelona Supercomputing Center-Centro Nacional de Supercomputación
DIGITAL.CSIC. Repositorio Institucional del CSIC
Publication Artículo científico (JournalArticle)

Targeting the FtsZ allosteric binding site with a novel fluorescence polarization screen, cytological and structural approaches for antibacterial discovery

  • Huecas, Sonia
  • Araújo-Bazán, Lidia
  • Ruiz, Federico M.
  • Ruiz-Avila, Laura B.
  • Martínez, R. Fernando
  • Escobar-Peña, Andrea
  • Artola, Marta
  • Vazquez-Villa, Henar
  • Martín-Fontecha, Mar
  • Fernández-Tornero, Carlos
  • Lopez-Rodriguez, M.L.
  • Andreu, José Manuel
51 p.-6 fig.-1 tab.-4 schem.-1 graph. abst., Bacterial resistance to antibiotics makes previously manageable infections again disabling and lethal, highlighting the need for new antibacterial strategies. In this regard, inhibition of the bacterial division process by targeting key protein FtsZ has been recognized as an attractive approach for discovering new antibiotics. Binding of small molecules to the cleft between the N-terminal guanosine triphosphate (GTP)-binding and the C-terminal subdomains allosterically impairs the FtsZ function, eventually inhibiting bacterial division. Nonetheless, the lack of appropriate chemical tools to develop a binding screen against this site has hampered the discovery of FtsZ antibacterial inhibitors. Herein, we describe the first competitive binding assay to identify FtsZ allosteric ligands interacting with the interdomain cleft, based on the use of specific high-affinity fluorescent probes. This novel assay, together with phenotypic profiling and X-ray crystallographic insights, enables the identification and characterization of FtsZ inhibitors of bacterial division aiming at the discovery of more effective antibacterials., Thiswork was supported by grants BFU 2014-51823-R (J.M.A.),SAF2016-78792-R, PID2019-106279RB-I00 (M.L.L.-R.), BFU2017-87387-P (C.F.-T.), and predoctoral FPU fellowshipsfrom MECD (A.E.-P. and M.A.)., Peer reviewed